Cover Image
市場調查報告書

EpiCast Report:肢端肥大症、巨人症──流行病學的預測

EpiCast Report: Acromegaly and Gigantism - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 320341
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:肢端肥大症、巨人症──流行病學的預測 EpiCast Report: Acromegaly and Gigantism - Epidemiology Forecast to 2023
出版日期: 2014年12月01日 內容資訊: 英文 58 Pages
簡介

肢端肥大症、巨人症為腦下垂體的難治之症的一種,特徵是生長激素(GH)過剩分泌。生長激素到成人期之後開始過剩分泌被稱作肢端肥大症,另一方面從幼兒期開始的稱作巨人症。在全球主要6個國家診斷出肢端肥大症的患病人數,2013年達25,354人,到2023年預計達26,884人。同樣的,診斷出巨人症的診斷患病人數,2013年達591人,到2023年預計達621人。肢端肥大症、巨人症的患者接受任何方式外科治療的患者數,2013年達22,408人,,到2023年預計達23,765人被預測。

本報告提供全球主要國家的肢端肥大症及巨人症的發病情形與今後預測相關分析、疾病的特徵,及目前患病者的發病情形、今後10年的患病數量的預測值等調查評估。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 肢端肥大症的流行病學的預測(今後11年份)
    • 肢端肥大症的確診的患者數
    • 已診斷出肢端肥大症的患者數患者數:各年齡
    • 已診斷出肢端肥大症的患者數患者數:男女
    • 已診斷出肢端肥大症的患者數患者數(已調整年齡)
  • 巨人症的流行病學的預測(今後11年份)
    • 已診斷出巨人症的患者數
    • 已診斷出巨人症的患者數:各年齡
    • 已診斷出巨人症的患者數:男女
    • 已診斷出巨人症的患者數(年齡已調整的)
  • 肢端肥大症、巨人症患者中,是否併發巨大腺瘤、微小腺瘤,接受任何外科治療的人的流行病學預測(今後11年份)
    • 已診斷出肢端肥大症、巨人症的患者中併發巨大腺瘤的人
    • 已診斷出肢端肥大症、巨人症的患者中併發微小腺瘤的人
    • 肢端肥大症、巨人症患者的患者中接受任何外科治療的人
  • 討論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

目錄
Product Code: GDHCER070-14

Acromegaly and gigantism are rare disorders of the pituitary gland characterized by the hypersecretion of growth hormone (GH). GH excess beginning in adulthood is known as acromegaly, whereas GH excess beginning during childhood is known as gigantism.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of acromegaly in the 6MM from 25,354 diagnosed prevalent cases in 2013 to 26,884 diagnosed prevalent cases in 2023, at an Annual Growth Rate (AGR) of 0.60% in the forecast period. Similarly, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of gigantism in the 6MM from 591 diagnosed prevalent cases in 2013 to 621 diagnosed prevalent cases in 2023, at an AGR of 0.51% in the forecast period. The 6MM had an estimated 22,408 diagnosed prevalent cases of acromegaly and gigantism receiving any surgical treatment in 2013, and the number of diagnosed prevalent cases of acromegaly and gigantism receiving any surgical treatment is expected to increase to 23,765 by 2023, at an AGR of 0.61%.

GlobalData epidemiologists utilized comprehensive, country-specific data from national acromegaly registers and peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed prevalent cases of acromegaly, as well as the diagnosed prevalent cases of gigantism. For all the 6MM, acromegaly and gigantism cases were segmented by age and sex, and then further segmented into the type of pituitary adenoma, and the need for surgical intervention. Additionally, the cases of acromegaly and gigantism used in this forecast fulfilled the most commonly used diagnostic criteria across the globe, which are based on GH and IGF-1 levels. Finally, the same forecast methodology was used across the 6MM, thereby allowing for meaningful global comparisons of the diagnosed prevalent cases of acromegaly, and the diagnosed prevalent cases of gigantism across these markets.

Scope

  • The Acromegaly and Gigantism EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for acromegaly and gigantism in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of acromegaly and gigantism, segmented by sex, age (in 15-year age groups beginning at 15 years and ending at ≥75 years in acromegaly cases, and beginning at 0 years and ending at ≥75 years in gigantism cases), type of pituitary adenoma (macroadenoma or microadenoma), and whether any surgical intervention was received in these markets.
  • The acromegaly and gigantism epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

The acromegaly and gigantism EpiCast series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global acromegaly and gigantism market.
  • Quantify patient populations in the global acromegaly and gigantism market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for acromegaly and gigantism therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Acromegaly (2013-2023)
    • 3.5.1. Diagnosed Prevalent Cases of Acromegaly
    • 3.5.2. Age-Specific Diagnosed Prevalent Cases of Acromegaly
    • 3.5.3. Sex-Specific Diagnosed Prevalent Cases of Acromegaly
    • 3.5.4. Age-Standardized Diagnosed Prevalence of Acromegaly
  • 3.6. Epidemiological Forecast for Gigantism (2013-2023)
    • 3.6.1. Diagnosed Prevalent Cases of Gigantism
    • 3.6.2. Age-Specific Diagnosed Prevalent Cases of Gigantism
    • 3.6.3. Sex-Specific Diagnosed Prevalent Cases of Gigantism
    • 3.6.4. Age-Standardized Diagnosed Prevalence of Gigantism
  • 3.7. Epidemiological Forecast for Acromegaly and Gigantism with Macroadenomas, Microadenomas, and Cases Receiving Any Surgical Treatment (2013-2023)
    • 3.7.1. Diagnosed Prevalent Cases of Acromegaly and Gigantism with Macroadenomas
    • 3.7.2. Diagnosed Prevalent Cases of Acromegaly and Gigantism with Microadenomas
    • 3.7.3. Diagnosed Prevalent Cases of Acromegaly and Gigantism Receiving Any Surgical Treatment
  • 3.8. Discussion
    • 3.8.1. Epidemiological Forecast Insight
    • 3.8.2. Limitations of the Analysis
    • 3.8.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Acting Director of Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Acromegaly and Gigantism
  • Table 2: Summary of the Global Reported Cases and Estimated Prevalence of Acromegaly
  • Table 3: Global Consensus Criteria for the Diagnosis and Cure of Acromegaly
  • Table 4: Sources of Acromegaly and Gigantism Prevalence Data in the 6MM
  • Table 5: Sources of Macroadenoma, Microadenoma, and Surgery Data in the 6MM
  • Table 6: 6MM, Diagnosed Prevalent Cases of Acromegaly, Both Sexes, Ages ≥15 Years, N, 2013-2023
  • Table 7: 6MM, Age-Specific Diagnosed Prevalent Cases of Acromegaly, Both Sexes, N (Row %), 2013
  • Table 8: 6MM, Sex-Specific Diagnosed Prevalent Cases of Acromegaly, Ages ≥15 Years, N (Row %), 2013
  • Table 9: 6MM, Diagnosed Prevalent Cases of Gigantism, Both Sexes, All Ages, N, 2013-2023
  • Table 10: 6MM, Age-Specific Diagnosed Prevalent Cases of Gigantism, Both Sexes, N (Row %), 2013
  • Table 11: 6MM, Sex-Specific Diagnosed Prevalent Cases of Gigantism, All Ages, N (Row %), 2013

List of Figures

  • Figure 1: 6MM, Diagnosed Prevalent Cases of Acromegaly, Both Sexes, Ages ≥15 Years, N, 2013-2023
  • Figure 2: 6MM, Age-Specific Diagnosed Prevalent Cases of Acromegaly, Both Sexes, Ages ≥15 Years, N, 2013
  • Figure 3: 6MM, Sex-Specific Diagnosed Prevalent Cases of Acromegaly, Ages ≥15 Years, N, 2013
  • Figure 4: 6MM, Age-Standardized Diagnosed Prevalence of Acromegaly (Cases per Million Population), Ages ≥15 Years, by Sex, 2013
  • Figure 5: 6MM, Diagnosed Prevalent Cases of Gigantism, Both Sexes, All Ages, N, 2013-2023
  • Figure 6: 6MM, Age-Specific Diagnosed Prevalent Cases of Gigantism, Both Sexes, All Ages, N, 2013
  • Figure 7: 6MM, Sex-Specific Diagnosed Prevalent Cases of Gigantism, All Ages, N, 2013
  • Figure 8: 6MM, Age-Standardized Diagnosed Prevalence of Gigantism (Cases per Million Population), All Ages, by Sex, 2013
  • Figure 9: 6MM, Diagnosed Prevalent Cases of Acromegaly (Ages ≥15 Years) and Gigantism (All Ages) with Macroadenomas, Both Sexes, N, 2013 and 2023
  • Figure 10: 6MM, Diagnosed Prevalent Cases of Acromegaly (Ages ≥15 Years) and Gigantism (All Ages) with Microadenomas, Both Sexes, N, 2013 and 2023
  • Figure 11: 6MM, Diagnosed Prevalent Cases of Acromegaly (Ages ≥15 Years) and Gigantism (All Ages) Receiving Any Surgical Treatment, Both Sexes, N, 2013 and 2023
Back to Top